Vanderbilt Institute for Clinical and Translational Research (VICTR)

Gordon Bernard, MD, is stepping down from his institutional leadership roles next summer to focus on his research interests.
December 16, 2022

VUMC Announces VICTR Leadership Transition

By Bill Snyder
The clinical trial group includes, from left, Gordon Bernard, MD, Katherine Cahill, MD, Kevin Niswender, MD, PhD, Pingsheng Wu, PhD, and R. Stokes Peebles, MD.
November 10, 2022

Clinical trial at VUMC tests novel treatment for asthma

VUMC has begun enrolling patients with asthma in a clinical trial of a novel treatment: a medication approved to treat diabetes and obesity.

By Leigh MacMillan
(iStock)
October 6, 2022

VUMC to test whether Alzheimer’s drug can ease lupus symptoms

Vanderbilt University Medical Center is partnering with Evergreen Therapeutics Inc. to test whether an Alzheimer’s drug, memantine, can improve cognitive symptoms associated with systemic lupus.

By Bill Snyder
The REDCapCon in Boston drew 377 registrants from 263 institutions spanning 42 states and 22 countries on six continents.
September 29, 2022

Conference highlights REDCap’s global reach

REDCap administrators from around the world recently attended the 14th edition of REDCapCon in Boston, hosted this year by Harvard Catalyst, Harvard University’s center for clinical and translational science.

By Paul Govern
September 22, 2022

Self named co-principal investigator of Vanderbilt’s Clinical and Translational Science Award

Wesley Self, MD, MPH, a physician-scientist at Vanderbilt University Medical Center, has been named co-principal investigator (co-PI) of Vanderbilt’s Clinical and Translational Science Award (CTSA).  

By Bill Snyder
VUMC’s new automated biobanking system can store as many as 10 million biospecimens.
August 25, 2022

New high-tech biobank safeguards critical specimens

By Bill Snyder
August 17, 2022

Researchers discover how salt increases blood pressure

A Vanderbilt research team has discovered that activation of a certain protein complex involved in the inflammatory response in immune cells contributes to salt-sensitive hypertension.
By Leigh MacMillan
July 6, 2022

VUMC and Roivant Social Ventures announce collaboration to develop therapies for underserved populations

Vanderbilt University Medical Center and Roivant Social Ventures (RSV) this week announced an intention to collaborate in developing therapies for traditionally underserved populations and diseases.
By Bill Snyder
June 16, 2022

Researchers add sign language videos to electronic surveys

A new external module in Vanderbilt's REDCap improves electronic survey accessibility for respondents who are deaf. The module makes it easy to embed individual sign language videos for each survey question and answer.
By Paul Govern
April 6, 2022

Major grant renewal to provide five more years of support for VICTR

Vanderbilt University Medical Center has competed successfully for a third renewal of its Clinical and Translational Science Award by the National Institutes of Health.
By Bill Snyder
November 11, 2021

Translational Research Forum honors scientific excellence

Vanderbilt University Medical Center’s strength in translational research, which helps “translate” scientific discovery into medical practice, was celebrated recently during the Vanderbilt Translational Research Forum
By Bill Snyder
August 5, 2021

Facebook campaign quickly nets clinical trial participants

The cost and effectiveness of social media as a participant recruitment tool for clinical research is still being evaluated. To better understand its utility, researchers at Vanderbilt University Medical Center used Facebook to mount a short, monthlong pilot campaign in and around Houston attempting to recruit participants for an ongoing smoking cessation study being conducted in that city.
By Paul Govern
May 6, 2021

VUMC to lead national study to treat severe COVID complications

The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.
By Bill Snyder
1 2 3 4 … 7